Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. J Clin Pathol 2006 Dec;59(12):1327-30
Date
12/05/2006Pubmed ID
17142577Pubmed Central ID
PMC1860524DOI
10.1136/jcp.2005.035147Scopus ID
2-s2.0-33845983246 (requires institutional sign-in at Scopus site) 21 CitationsAbstract
Adenoid cystic/basal cell carcinoma (ACBCC) is a rare neoplasm in the prostate. Definitive treatment is warranted, as among 19 patients previously reported by us, 5 had extraprostatic extension and 4 were metastatic. The HER-2/neu (c-erbB-2) gene has been reportedly overexpressed in adenoid cystic carcinomas in other organs, but its status in prostatic ACBCC was uncertain. Immunohistochemical staining and in situ hybridisation were carried out in 13 patients with ACBCC (11 from transurethral resection, 2 prostatectomy). One patient had metastasis to the lung. Citrate buffer and steam heat were used for antigen retrieval. Ten acinar adenocarcinomas of varying grades were also immunostained as controls. Protein and mRNA expression were 2+ to 3+ (of 3+) in all patients with ACBCC, compared to a breast cancer control with strong reactivity, whereas protein expression was noted in only one acinar carcinoma and mRNA expression was absent in all acinar carcinomas. Benign acini expressed HER-2/neu only in the basal layer. The finding of strong, consistent HER-2/neu expression in ACBCC suggests that treatment with Herceptin (trastuzumab) may be effective in patients with this rare tumour.
Author List
Iczkowski KA, Montironi RMESH terms used to index this publication - Major topics in bold
AdultAged
Carcinoma, Adenoid Cystic
Carcinoma, Basal Cell
Gene Expression
Humans
In Situ Hybridization
Male
Middle Aged
Mixed Tumor, Malignant
Prostatic Neoplasms
RNA, Messenger
RNA, Neoplasm
Receptor, ErbB-2
